What Lupin disclosed
Lupin disclosed a press release under Regulation 30 stating that the U.S. Food and Drug Administration has granted tentative approval for its New Drug Application for Apixaban Oral Suspension 1.25 mg/mL, filed through the 505(b)(2) regulatory pathway. Per the filing, a tentative approval means the FDA finds the application meets required standards, but final approval — and marketing — cannot proceed until certain conditions, typically patent or exclusivity matters, are resolved.
A liquid formulation, not a plain generic
According to the filing, the product is an oral liquid formulation of apixaban, the active ingredient in Bristol Myers Squibb's Eliquis. Lupin said it offers an alternative administration option for adult patients requiring anticoagulation therapy, including those who may have difficulty swallowing tablets, and framed the approval as part of its focus on differentiated medicines rather than conventional generics. Upon final approval, the filing said, the product would be manufactured at Lupin's Somerset, New Jersey facility.
Why it matters to a holder
The disclosure marks a regulatory milestone on a specialty product for the U.S., which the company identifies as a core market. Because the approval is tentative, the filing states no launch date, and no revenue, sales-potential, or financial figures were disclosed. Any commercial impact depends on final approval, which is outside the scope of this filing.